Genei Laboratories, a Bengaluru-based biotech company, has got the licence from IIT-Delhi to manufacture and commercialise the latter’s low-cost, real-time PCR diagnostic assay kit for Covid-19.
The National Biomedical Resource Indigenization Consortium (NBRIC), which facilitated the licensing, said IIT-Delhi is the first academic institute in India to get ICMR (Indian Council of Medical Research) approval for the indigenously developed kit.
As per the agreement, Genei Labs holds a non-exclusive licence from IIT-Delhi to scale up production and go to market with the kit. While standard RT-PCR kits in the market are probe-based, this design does away with probes completely. Instead, it detects Covid-19-specific RNA sequence in samples. As a result, the cost of testing is reduced to a fraction, making the kit affordable.
Genei will manufacture the kits in an exclusive Covid-19 testing kit manufacturing facility at the Andhra Pradesh MedTech Zone (AMTZ) in Visakhapatnam. The kit is expected to be rolled out in early June.
“We are thankful to IIT Delhi-and AMTZ for considering Genei Labs for further development and large-scale manufacture of this unique detection assay for Covid-19. Using Genei Labs’ expertise in reagent manufacturing and kit-making, we will ensure an accurate, affordable, Make-in-India RT-PCR kit for the diagnosis of Covid-19,” said S Chandrashekaran, Managing Director, Genei Laboratories.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.